Cargando…
Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients
OBJECTIVES: Randomized clinical trials do not include a population that truly reflects a real-world population, due to their inclusion and exclusion criteria. This leads to concerns about the applicability of these studies in a clinical practice. In the present study, we aim to describe the clinical...
Autores principales: | Christensen, Thomas, Berg, Tobias, Nielsen, Lise Birk, Andersson, Michael, Jensen, Maj-Britt, Knoop, Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375653/ https://www.ncbi.nlm.nih.gov/pubmed/32200206 http://dx.doi.org/10.1016/j.breast.2020.03.002 |
Ejemplares similares
-
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With
Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based
Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022) -
Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)
por: Berg, Tobias, et al.
Publicado: (2020) -
High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
por: Nielsen, Kåre, et al.
Publicado: (2023) -
Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
por: Celik, Alan, et al.
Publicado: (2023) -
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)